Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R -targeted therapy (daclizumab) in multiple sclerosis Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R -targeted therapy (daclizumab) in multiple sclerosis2018-01-17T17:00:33-05:00
